Gonorrhea Treatment: Current CDC-Recommended Regimen
Uncomplicated Gonorrhea: First-Line Therapy (CDC 2021 Guidelines)
Ceftriaxone 500 mg IM single dose (for persons <150 kg; 1 g IM if ≥150 kg).
Key Updates from Prior Guidelines
- Dose increased from 250 mg → 500 mg due to rising MICs (minimum inhibitory concentrations).
- Azithromycin 1 g oral no longer routinely recommended (rising macrolide resistance, no added benefit for uncomplicated GC).
- Doxycycline 100 mg BID × 7 days added if chlamydia not ruled out (co-treatment).
Alternative Regimens (If Ceftriaxone Unavailable/Allergy)
- Gentamicin 240 mg IM single dose PLUS Azithromycin 2 g oral single dose
- Cefixime 800 mg oral single dose (less effective for pharyngeal infection)
Special Situations
| Scenario | Management |
|---|---|
| Pharyngeal gonorrhea | Ceftriaxone 500/1000 mg IM only (cefixime unreliable) |
| Pregnancy | Ceftriaxone 500 mg IM (safe); test-of-cure at 3–4 weeks |
| Cephalosporin allergy (anaphylaxis) | Gentamicin 240 mg IM + Azithromycin 2 g oral; consult specialist |
| Disseminated GC (arthritis-dermatitis) | Ceftriaxone 1 g IV/IM q24h × 7 days; switch to oral after 24–48 hrs improvement |
